TuHURA Biosciences Files 8-K

TL;DR

TuHURA Bio filed an 8-K on Dec 9th - material agreement and other events.

AI Summary

TuHURA Biosciences, Inc. (formerly Kintara Therapeutics, Inc.) filed an 8-K on December 10, 2025, reporting the entry into a material definitive agreement and other events. The company, incorporated in Nevada with its principal business address in Tampa, Florida, operates in the Pharmaceutical Preparations sector.

Why It Matters

This filing indicates significant corporate activity or agreements for TuHURA Biosciences, which could impact its operational status and future business direction.

Risk Assessment

Risk Level: medium — 8-K filings often signal material changes, but the specific nature of the agreement or event is not detailed here, requiring further investigation.

Key Numbers

• 001-37823 — SEC File Number (Identifies the company's filing history with the SEC.)
• 99-0360497 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

• TuHURA Biosciences, Inc. (company) — Registrant
• Kintara Therapeutics, Inc. (company) — Former company name
• DelMar Pharmaceuticals, Inc. (company) — Former company name
• Berry Only Inc. (company) — Former company name
• Nevada (jurisdiction) — State of incorporation
• Tampa, FL (location) — Business address
• December 9, 2025 (date) — Date of earliest event reported
• December 10, 2025 (date) — Date of report

FAQ

Key Financial Figures

• $0.001 — ange on which registered Common Stock, $0.001 par value per share HURA The Nasdaq
• $1.65 — ries A Warrant and Series B Warrant was $1.65. Each Common Warrant has an exercise pr
• $1.95 — Common Warrant has an exercise price of $1.95 per share and is exercisable beginning
• $5 million — ent, K&V shall fund (i) with respect to $5 million of K&V's subscription amount, at a date
• $2 million — ond Closing"), and (ii) with respect to $2 million of K&V's subscription amount, at a date
• $8.6 million — roceeds to the Company of approximately $8.6 million from the First Closing, approximately $
• $3.4 b — capital, satisfaction of the Company's $3.4 bridge note obligation to the Matthew Nac
• $1.75 million — atthew Nachtrab Revocable Trust (net of $1.75 million invested by such lender into the Offeri
• $100,000 — s of counsel in an amount not to exceed $100,000, and (iv) $25,000 for non-accountable e
• $25,000 — amount not to exceed $100,000, and (iv) $25,000 for non-accountable expenses. In additi
• $2.0625 — the Offering), at an exercise price of $2.0625 per share, which represents 125% of the

Filing Documents

• d79925d8k.htm (8-K) — 40KB
• d79925dex41.htm (EX-4.1) — 84KB
• d79925dex42.htm (EX-4.2) — 84KB
• d79925dex43.htm (EX-4.3) — 84KB
• d79925dex51.htm (EX-5.1) — 14KB
• d79925dex101.htm (EX-10.1) — 185KB
• d79925dex102.htm (EX-10.2) — 11KB
• d79925dex991.htm (EX-99.1) — 12KB
• g79925g29h70.jpg (GRAPHIC) — 5KB
• g79925g43x94.jpg (GRAPHIC) — 4KB
• 0001193125-25-314302.txt ( ) — 779KB
• hura-20251209.xsd (EX-101.SCH) — 3KB
• hura-20251209_lab.xml (EX-101.LAB) — 18KB
• hura-20251209_pre.xml (EX-101.PRE) — 11KB
• d79925d8k_htm.xml (XML) — 4KB

Financial Statements and Exhibits

Financial Statements and Exhibits. (d)Exhibits. Exhibit No. Description 4.1 Form of Series A Purchase Warrant 4.2 Form of Series B Purchase Warrant 4.3 Form of Placement Agent Warrant 5.1 Opinion of Foley & Lardner LLP 10.1* Form of Securities Purchase Agreement, dated as of December 9, 2025, by and among the Company and the Purchasers named therein 10.2 Side Letter Agreement, dated December 9, 2025, between the Company and K&V Investment One LLC 23.1 Consent of Foley & Lardner LLP (included in Exhibit 5.1) 99.1 Press Release, dated December 9, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). * Certain of the exhibits and schedules to this exhibit have been omitted in accordance with Regulation S-K Item 601(a)(5). The Company agrees to furnish a copy of all omitted exhibits and schedules to the SEC upon its request.

Forward-Looking Statements

Forward-Looking Statements This Current Report includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements contained herein that do not describe historical facts, including, but not limited to, statements relating to the expected net proceeds of the Offering, the anticipated use of proceeds of the Offering, and the timing of the closing of the Offering, are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements. You are cautioned that such statements are not guarantees of future performance and that the Company's actual results may differ materially from those set forth in the forward-looking statements. All of these forward-looking statements are subject to risks and uncertainties that may change at any time. Factors that could cause the Company's actual expectations to differ materially from these forward-looking statements include the Company's liquidity needs to operate its business and execute its strategy, and related use of cash; its ability to raise capital through equity issuances, asset sales or the incurrence of debt; retail and credit market conditions; higher cost of capital and borrowing costs; impairments; changes in general economic conditions; and the other factors under the heading "Risk Factors" set forth in the Company's Annual Report on Form 10-K, as supplemented by the Company's quarterly reports on Form 10-Q and current reports on Form 8-K. Such filings are available on our website or at www.sec.gov. You should not place undue reliance on these forward-looking statements, which are made only as of the date hereof. The Company undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent developments, events, or circumstances, except as may be required under applicable securities laws.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TUHURA BIOSCIENCES, INC. Date: December 10, 2025 By: /s/ Dan Dearborn Name: Dan Dearborn Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR